跳至主要内容
临床试验/NCT01806207
NCT01806207已完成4 期

A Double-blind, Randomized, Multi-centre Study of the Efficacy and Safety of a Single Intra-articular Injection With Durolane Compared to Saline in Patients With Unilateral Knee Osteoarthritis

Galderma R&D1 个研究点 分布在 1 个国家目标入组 218 人开始时间: 2003年2月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
发起方
Galderma R&D
入组人数
218
试验地点
1
主要终点
Proportion of responders at 6 weeks.

研究概览

简要总结

This was a study that compared Durolane injections to saline injections in the treatment of unilateral osteoarthritis of the knee. The patients were randomly assigned one of the two treatments unaware of which treatment they received. The study was conducted at 13 centers in Germany, the United Kingdom and Sweden. Patients were followed for six weeks after study treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Osteoarthritis according to ACR (American College of Radiology) criteria for the knee
  • •WOMAC pain score in the range 7 to 17
  • •Significant knee pain for the majority of days during the past 3 months
  • •Patient normally active, not bedridden or confined to a wheelchair and able to walk 50 meters without the help of a walker, crutches or a cane
  • •Patient has attempted but not responded adequately to non-pharmacological therapy(ies)
  • •Patient co-operative and able to communicate effectively with the investigators
  • •Signed informed consent obtained

排除标准

  • •Bilateral knee osteoarthritis
  • •Osteoarthritis or clinically significant pain from other part of the musculoskeletal system than the study knee
  • •Kellgren Lawrence radiographic score grade IV for the study knee
  • •Change in physical therapy/occupational therapy for the knee within the last 3 months
  • •Treatment with nonsteroidal antiinflammatory drugs (NSAIDs) (including topical agents for the study knee) during the last week (or 5 half-lives of the drug, whichever is longer) prior to baseline visit
  • •Treatment with non-NSAID topicals such as capsaicin for the knee within the last 3 days
  • •Intra-articular injection with corticosteroids in the study knee within the last 3 months
  • •Use of systemic steroids (excluding inhalation steroids) within the last 3 months
  • •Intra-articular injections with hyaluronic acid in the study knee within the last 9 months
  • •Treatment with glucosamine/chondroitin sulfate within the last 3 months
  • •Treatment with pain relievers except for paracetamol up to 4g/day
  • •Treatment with anticoagulant (except for acetylsalicylic acid max. 325 mg/day)
  • •Arthroscopy or any other surgical procedure in the study knee within the last 12 months
  • •Planned arthroscopy or any other surgical procedure during the study period
  • •Any medical condition which in the opinion of the investigator makes the patient unsuitable for inclusion (e.g. severe progressive chronic disease, malignancy, bleeding disorder, fibromyalgia)
  • •Systemic active inflammatory condition or infection, such as Rheumatoid arthritis, inflammatory arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, gout/acute pseudogout or any other connective tissue disease
  • •Septic arthritis in the study knee within the last 3 months
  • •Active skin disease or infection in the area of the injection site
  • •Significant venous or lymphatic stasis present in the legs
  • •Pregnant or breast-feeding woman or woman of child-bearing potential not practicing adequate contraception
  • •Subjects that in the opinion of the investigator are unsuitable for inclusion (e.g. subjects not likely to avoid other therapies, subjects not likely to stay in the study during the whole study period, or subjects likely to be unreliable)
  • •Concurrent participation in any other clinical study or participation within the preceding 30 days

研究组 & 干预措施

Durolane injection

Active Comparator

Intraarticular injection of 3 ml Durolane.

干预措施: Durolane injection (Device)

Saline injection

Placebo Comparator

Intraarticular injection of physiological sodium chloride (0.9% NaCl) solution pH 7.

干预措施: Saline injection (Other)

结局指标

主要结局

Proportion of responders at 6 weeks.

时间窗: At 6 weeks after treatment

Proportion of responders was based on the improvement in WOMAC (Western Ontario and McMasters Universities Osteoarthritis Index) pain score.

次要结局

  • Patient assessed global status(2, 4 and 6 weeks after treatment)
  • WOMAC pain score(2 and 4 weeks after treatment)
  • Safety of intraarticular injections of 3 ml Durolane(Through 6 weeks after treatment)
  • WOMAC stiffness score(2, 4 and 6 weeks after treatment)
  • WOMAC physical function score(2, 4 and 6 weeks after treatment)

研究者

发起方
Galderma R&D
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验